Stefan Gross, Executive Director and Head of Molecular Discovery at Servier Pharmaceuticals, shared on LinkedIn:
“Proud to be with the Servier team at the Prix Galien International Awards, and grateful to collaborate with such dedicated colleagues who share a deep commitment to precision oncology and improving outcomes for patients worldwide.”
Servier Pharmaceuticals, shared on LinkedIn:
“Servier was honored to attend the 2026 International Prix Galien Awards, joining leaders from across the global life sciences community to celebrate the scientific innovation shaping the future of patient care.
We were especially proud to be recognized as a finalist for the inaugural Patient First Award in Honor of Michael J. Fox, a distinction celebrating organizations that make a meaningful difference in the lives of patients through innovation, advocacy, and an unwavering commitment to care.
Servier was also recognized with nominations for two medicines in the Best Product for Orphan/Rare Disease and Best Pharmaceutical Product categories for our therapy for Grade 2 IDH-mutant glioma and our therapy for AML, MDS, and CCA.
Congratulations to this year’s award recipients and fellow finalists, and thank you to The Galien Foundation for continuing to elevate scientific excellence and patient-centered innovation across the global life sciences community.”
Other articles about Precision Oncology on OncoDaily.